Denosumab a new treatment for postmenopausal osteoporosis

Christopher J. Yates, Peter R. Ebeling

Research output: Contribution to journalShort SurveyOtherpeer-review


Denosumab (Prolia) is a promising new first-line agent for the treatment of postmenopausal osteoporosis with proven fracture risk reduction.

Original languageEnglish
Pages (from-to)61-63
Number of pages3
JournalMedicine Today
Issue number6
Publication statusPublished - Jun 2011
Externally publishedYes

Cite this